The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX

Journal of Psychopharmacology
Bob WilffertPeter N van Harten

Abstract

Tardive dyskinesia (TD) is associated with polymorphisms of the dopamine D(3), serotonin 2A and 2C receptors (DRD3, HTR2A and HTR2C, respectively). This study investigated the possible relationship between TD and the polymorphisms Ser9Gly (DRD3), 102T>C (HTR2A), -1438G>A(HTR2A) and Cys23Ser (HTR2C) in African-Caribbean inpatients. One hundred and twenty-six patients under chronic antipsychotic treatment were genotyped. The assessment of TD was carried out with the abnormal involuntary movement scale (AIMS). The relationships between the carriership of the least frequent alleles and the respective orofaciolingual dyskinesia (TDof) (sum of the items 1-4 of the AIMS), limb-truncal dyskinesia (TDlt) (sum of items 5-7 of the AIMS) and TD (sum of items 1-7 of the AIMS) were analyzed with ANCOVA, comparing means with age as a covariate and stratification for carriers and non-carriers of the mutations. In addition, we conducted pre-planned t-tests to compare AIMS values of carriers of the combinations of alleles versus the corresponding non-carriers. In the study population, females with 9Ser carriership exhibited higher AIMS values than non-carriers. Male subjects with 9Ser carriership in combination with 23Ser or -1438A carriership e...Continue Reading

References

Jul 1, 1976·Archives of General Psychiatry·J M Davis
Oct 1, 1989·International Clinical Psychopharmacology·H YoussefF Youssef
Aug 1, 1988·Journal of Clinical Psychopharmacology·G M SimpsonM J Stephanos
Feb 11, 1988·Nucleic Acids Research·S A MillerH F Polesky
Dec 1, 1981·The American Journal of Psychiatry·R Yassa, J Ananth
Nov 1, 1994·Pharmacology, Biochemistry, and Behavior·H RosengartenA J Friedhoff
Jan 1, 1993·Schizophrenia Bulletin·D V Jeste, M P Caligiuri
Dec 10, 1997·The Annals of Pharmacotherapy·E J FrackiewiczN R Cutler
Nov 28, 2001·Acta Psychiatrica Scandinavica·D J MüllerMarcella Rietschel
Jun 14, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bernard LererFabio Macciardi
Sep 28, 2002·Human Molecular Genetics·Vincenzo S BasileJames L Kennedy
Dec 24, 2002·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Siow-Ann ChongYiong Huak Chan
Apr 25, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Hasan HerkenHaluk A Savaş
Aug 11, 2004·Pharmacology, Biochemistry, and Behavior·Peter MalikLinda Peacock
Sep 24, 2004·The International Journal of Neuropsychopharmacology·Enrico LattuadaEnrico Smeraldi
Jun 2, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Gara L CoffeyJose de Leon
Jun 15, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Gavin P ReynoldsZhi Jun Zhang

Citations

Apr 28, 2011·Pharmacogenomics·Bob WilffertLolkje T W de Jong-van den Berg
Jul 14, 2011·Psychopharmacology·Jeroen P KoningGenetic Risk and Outcome in Psychosis (GROUP) investigators
Oct 25, 2013·International Review of Psychiatry·C Anthony AltarDavid Mrazek
Dec 18, 2010·Expert Opinion on Drug Metabolism & Toxicology·Jian-Ping Zhang, Anil K Malhotra
Sep 14, 2010·Clinics in Laboratory Medicine·Peter P Zandi, Jennifer T Judy
Dec 1, 2015·Pharmacology & Therapeutics·Giuseppe Di Giovanni, Philippe De Deurwaerdère
Feb 18, 2010·The Psychiatric Clinics of North America·Peter P Zandi, Jennifer T Judy
Aug 7, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·James T TeoKailash Bhatia
Aug 19, 2014·Journal of Neural Transmission·Chiara FabbriAlessandro Serretti
Sep 17, 2016·Pharmacogenomics·Carolina Céspedes-GarroEva M Peñas-LLedó
Dec 17, 2009·Psychiatric Genetics·Gabriela NovakBernard Le Foll
Jun 4, 2010·Expert Review of Neurotherapeutics·Nicte I Mejia, Joseph Jankovic
Nov 26, 2011·Expert Review of Clinical Pharmacology·Maria J Arranz, Janet C Munro
Jul 29, 2017·Expert Review of Neurotherapeutics·Haitham SalemAntonio L Teixeira
Sep 1, 2015·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·K A KirnichnayaE M Krupitsky
Jun 3, 2014·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Eva J BrandlD J Müller

Related Concepts

Senility
Alleles
DNA, Double-Stranded
Dyskinesia, Medication-Induced
Genetic Equilibrium
Genetic Carriers
Antipsychotic Effect
Variation (Genetics)
African Continental Ancestry Group
Receptor, Serotonin,5-HT2A

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.